Canaccord Genuity analyst Kyle Mikson CFA has maintained their bullish stance on PACB stock, giving a Buy rating on January 7.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kyle Mikson CFA has given his Buy rating due to a combination of factors that signal an improving trajectory for Pacific Biosciences. The company’s preliminary fourth-quarter and full-year 2025 results exceeded both his estimates and consensus expectations, highlighted by a sharp quarter-over-quarter recovery in instrument sales and record consumables revenue. He interprets the rebound in instrument demand, alongside reduced cash burn and a stronger balance sheet, as early evidence that the business is emerging from a difficult 2025 that was weighed down by NIH funding pressures and geopolitical headwinds. In his view, the current share price fails to fully capture this operational inflection or the company’s long-term growth prospects.
Looking ahead, Mikson sees multiple drivers that can support sustained growth into 2026 and beyond. He points to the planned broad commercial rollout of multi-use SMRT cells and the new SPRQ-Nx chemistry as key initiatives that should lower sequencing costs, broaden applications, and enhance Pacific Biosciences’ competitive position in both research and clinical markets. He also highlights expanding clinical adoption, including new collaborations in rare disease and unexplained pediatric mortality, as important validation of the company’s technology and a foundation for durable demand as clinical revenue grows as a share of the business. Collectively, these operational, technological, and strategic developments underpin his conviction that Pacific Biosciences shares merit a Buy rating at current valuation levels.
In another report released on January 7, TD Cowen also maintained a Buy rating on the stock with a $3.00 price target.